Skip to main content
OpenTrials
Completed

NCT Number: NCT06550271

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals

This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Aging

Age range

40 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

AgelessRx

Ann Arbor, Michigan, 48104, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Receive AgelessRx's standard Rapamycin treatment protocol
  • Opted to complete at least 1 blood draw at their local Quest Lab

Exclusion criteria

  • Not approved for current AgelessRx standard Rapamycin treatment
  • History of uncontrolled disease
  • Unable to complete at least 1 blood draw at their local Quest Lab

Treatment and study plan

Rapamycin

Drug

Rapamycin in 2 different dosage forms (compounded and generic)

Other names: Sirolimus, Rapamune, Rapacan, Siromus, Raparen, Rapasim, Sirova

Primary outcomes

  1. define the relative bioavailability ratio between compounded rapamycin and generic rapamycin

    Time frame: 8 months

    define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).

Sponsors and collaborators

Lead sponsor

AgelessRx

Industry

Registry information

Official study title

The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals: A Retrospective Study and Review With Clinical Implications

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
Aug 13, 2024
Registry last updated
Aug 13, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.